Since it is highly and specifically expressed in tumor tissues, TRA16 may be used as a tumor-specific therapeutic target for lung cancer treatments in the form of anti-TRA16 antibody or TRA16 shRNA. This evidence concerns the gene NR2C2AP and lung carcinoma.